Hikma expands generics portfolio with Everolimus Tablets launch
London, March 13, 2020 – Hikma Pharmaceuticals PLC (Hikma, Group), the multinational generic pharmaceutical company, has launched Everolimus Tablets, 0.25mg, 0.50mg and 0.75mg, the generic equivalent to Zortress®, in the United States through its US affiliate, Hikma Pharmaceuticals USA Inc.
“We are very pleased to be providing patients and health care providers in the US with a generic version of this important medicine,” said Brian Hoffmann, President of Generics. “The launch of Everolimus Tablets expands our diversified portfolio of generic medicines in the US and, as a paragraph IV product, demonstrates our ability to successfully litigate and bring greater value to our customers and patients in the US.”
According to IQVIA, US sales of Everolimus Tablets, 0.25mg, 0.50mg and 0.75mg, were approximately $150 million in the 12 months ending January 2020.
Everolimus Tablets are indicated for:
- Prophylaxis of Organ Rejection in Kidney Transplantation
Everolimus is indicated for the prophylaxis of organ transplantation in adult patients at low-moderate immunologic risk receiving a kidney transplant. Everolimus is to be administered in combination with basiliximab induction and concurrently with reduced doses of cyclosporine and with corticosteroids. Therapeutic drug monitoring (TDM) of Everolimus and cyclosporine is recommended for all patients receiving these products.
- Prophylaxis of Organ Rejection in Liver Transplantation
Everolimus is indicated for the prophylaxis of allograft rejection in adult patients receiving a liver transplant. Everolimus is to be administered no earlier than 30 days posttransplant concurrently in combination with reduced doses of tacrolimus and with corticosteroids. TDM of Everolimus and cyclosporine is recommended for all patients receiving these products.
(LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (rated Ba1/stable Moody's and BB+/positive S&P)
Hikma helps put better health within reach every day for millions of people in more than 50 countries around the world. For more than 40 years, we've been creating high-quality medicines and making them accessible to the people who need them. Headquartered in the UK, we are a global company with a local presence across the United States (US), the Middle East and North Africa (MENA) and Europe, and we use our unique insight and expertise to transform cutting-edge science into innovative solutions that transform people's lives. We're committed to our customers, and the people they care for, and by thinking creatively and acting practically, we provide them with a broad range of branded and non-branded generic medicines. Together, our 8,600 colleagues are helping to shape a healthier world that enriches all our communities. We are a leading licensing partner, and through our venture capital arm, are helping bring innovative health technologies to people around the world. For more information, please visit: www.hikma.com
 Zortress® is a registered trademark of Novartis AG